title: Treatment of multibacillary leprosy with a regimen of 13 weeks duration.
abstract: In a prospective study 559 multibacillary patients in Zaire were treated for 13 weeks with twice weekly rifampicin (600 mg) and daily ethionamide (500 mg) and dapsone (100 mg), 13-RED, or clofazimine (100 mg), 13-REC. The patients were followed for a total of 1418 person years, mean 3.2 years. The incidence of hepatitis was 3.3%. The incidence of relapses was 0.28 per 100 person years. Relapses were due to drug-sensitive organisms. In patients who received the same drug regimens but with a reduced dosage of ethionamide to 5 mg/k bodyweight, the incidence of hepatitis was significantly lower but the relapse rate was 7.8 per 100 person years of follow-up in the RED group, no relapses were diagnosed in the REC group. It is concluded that by the use of potent antileprosy drugs in suitable combinations and dosages, it will be possible to shorten the duration of antibacterial treatment in multibacillary leprosy to 3 months.
authors.affiliation: University of Antwerp, Belgium.
authors.forename: S R
authors.initials: SR
authors.lastname: Pattyn
authors.forename: G
authors.initials: G
authors.lastname: Groenen
authors.forename: L
authors.initials: L
authors.lastname: Janssens
authors.forename: L
authors.initials: L
authors.lastname: Kuykens
authors.forename: L B
authors.initials: LB
authors.lastname: Mputu
mesh_terms: D002991:Clofazimine / Q000008:administration & dosage; D003622:Dapsone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005000:Ethionamide / Q000008:administration & dosage; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D005000:Ethionamide